Errata sheet regarding the publication “The Impella device questioned in the post-approval studies due to an increase of adverse events”

What was published in our website refers to the original publication by the FDA (Increased rate of mortality in patients receiving Abiomed Impella RP System – letter to health care providers) where, inadvertently, it was excluded from the title that the FDA communication referred exclusively to the Impella RP device.

The Impella circulatory assistance system comprises 4 different devices:

. Impella CP (the only model approved to be used in a LATAM country as Brazil).

. Impella 2.5 and Impella 5.0: for left ventricular assistance.

. Impella RP: for right ventricular assistance. It is this device in particular that the aforementioned published article refers to. This article is nothing but a summary of the FDA communication.

The lack of specification of the acronym RP in the title, referring to this particular model, could lead doctors reading only the title of the article to generalize these results to the rest of devices. This would, without a doubt, jeopardize left assistance models that have proven their benefits in the context of complex angioplasties and cardiogenic shock. By reading the full text of the article it is clear to which model it is referring to, but this is not so in the title, reason for which we believe it’s convenient to publish the present errata sheet.

Soon, we will publish a recent analysis of over 15,000 patients in the US that have benefitted from left assistance.

More articles by this author

FLAVOUR Trial Substudy: FFR or IVUS in the Assessment of Diabetic Patients

Patients with diabetes often present with more complex coronary artery disease compared to non-diabetic patients, with a higher prevalence of diffuse or multivessel disease....

ROLLER COASTR-EPIC22: Comparison of Plaque Modification Techniques in Severely Calcified Coronary Lesions

The presence of coronary calcium significantly limits the success of percutaneous coronary interventions (PCI), primarily due to suboptimal stent expansion. This can lead to...

Provisional Stenting vs. Two-Stent Technique in Non-Complex Left Main Disease: Three-Year Follow-Up of the EBC-Main Study

In left main coronary artery (LMCA) disease, for lesions of low to intermediate complexity according to the SYNTAX score, percutaneous coronary intervention (PCI) has...

RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions

Moderate or severe coronary calcification can be a marker of poor prognosis in coronary artery disease, as it significantly increases the risk of failure...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...